carisbamate
Small moleculeexperimental
Carisbamate is an experimental anticonvulsant drug that was under development by Johnson & Johnson Pharmaceutical Research and Development but never marketed. — Wikipedia
Clinical trial activity
21 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
18
Phase 3
9
Phase 4
0
Earliest trial started Mar 1, 2002 (NCT00109083)
Timeline
Indications
Studied for
- Alcoholism · Phase 1/Phase 2
- Diabetic Neuropathies · Phase 2
- Drug Resistant Epilepsy · Phase 2
- Epilepsies, Partial · Phase 3
- Epilepsy · Phase 3
- Epilepsy, Complex Partial · Phase 3
- Epilepsy, Partial, Motor · Phase 3
- Essential Tremor · Phase 2
- Healthy Volunteers · Phase 1
- Herpes Zoster · Phase 2
- Lennox Gastaut Syndrome · Phase 3
- Migraine Disorders · Phase 2
- Neuralgia · Phase 2
- Neuralgia, Postherpetic · Phase 2
- Seizures · Phase 3
- Substance-Related Disorders · Phase 1/Phase 2
Mechanism of action
- Galanin receptor 1ACTIVATOR
GALR1 activator
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)OC[C@@H](O)c1ccccc1Cl- Mol. weight
- 215.64 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCarisbamate ↗
- ChEMBLCHEMBL2087003 ↗
Also known as
- carisbamate
- carisbamate
- carisbamate
- carisbamate
- carisbamate
- carisbamate
- carisbamate
- carisbamate
- jnj-10234094
- jnj-10234094
- rwj333369
- rwj 333369
- rwj-333369
- rwj-333369
- rwj-333369
- rwj-333369
- (s)-(1-2-chlorophenyl)-1,2-ethanediol 2-carbamate
- s-2-o-carbamoyl-1-o-chlorophenyl-ethanol
- ykp-509
- ykp-509
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05219617 | Phase 3 | Apr 28, 2022 | Arvelle |
| NCT04520360 | Phase 1 | Aug 27, 2020 | Arvelle, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT04062981 | Phase 1 | May 3, 2019 | Arvelle |
| NCT03731715 | Phase 1 | Feb 7, 2019 | Arvelle |
| NCT02435381 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2013 | Baylor University |
| NCT00870454 | Phase 2 | May 1, 2009 | Arvelle, Johnson and Johnson |
| NCT00744731 | Phase 3 | Jan 1, 2009 | Arvelle, Johnson and Johnson |
| NCT00740623 | Phase 3 | Jan 1, 2009 | Arvelle, Johnson and Johnson |
| NCT00697918 | Phase 3 | Mar 1, 2008 | Arvelle, Janssen Pharmaceutica NV |
| NCT00563459 | Phase 3 | Nov 1, 2007 | Arvelle, Johnson and Johnson |
| NCT00697762 | Phase 3 | Oct 1, 2007 | Arvelle, Janssen Pharmaceutica NV |
| NCT00524056 | Phase 2 | Aug 1, 2007 | Arvelle, Johnson and Johnson |
| NCT00501202 | Phase 2 | Mar 1, 2007 | Arvelle, Johnson and Johnson |
| NCT00492323 | Phase 2 | Mar 1, 2007 | Arvelle, Johnson and Johnson |
| NCT00991757 | Phase 3 | Feb 1, 2007 | Arvelle, Johnson and Johnson |
| NCT00425282 | Phase 3 | Nov 1, 2006 | Arvelle, Johnson and Johnson |
| NCT00433667 | Phase 3 | Nov 1, 2006 | Arvelle, Johnson and Johnson |
| NCT00210522 | Phase 2 | May 1, 2005 | Arvelle, Johnson and Johnson |
| NCT00228969 | Phase 2 | Feb 1, 2005 | Arvelle |
| NCT00210652 | Phase 2 | Jul 1, 2004 | Arvelle, Johnson and Johnson |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arvelle | For profit | 20 | 20 | 3 | 2002 |
| Johnson and Johnson | For profit | 13 | 0 | 2 | 2002 |
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 1 | 2007 |
| Baylor University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1